Interferons (IFN-α, IFN-β, IFN-γ): Functions and Clinical Uses

Overview

Interferon Alpha (IFN-α) — Type I

Functions

• Produced rapidly (within hours) in response to double-stranded RNA (dsRNA), the replication intermediate of RNA viruses, and by interaction of enveloped viruses (HSV, HIV) with plasmacytoid dendritic cells (pDCs)
• Binds the IFNAR1/IFNAR2 heterodimeric receptor → activates JAK-STAT signaling → induces the antiviral state in neighboring cells
• The antiviral state involves two key enzymes:
  • 2',5'-oligoadenylate synthetase → activates RNase L → degrades viral mRNA
  • Protein kinase R (PKR) → phosphorylates eIF-2α → inhibits ribosome assembly and protein synthesis
• Upregulates MHC class I expression → enhances antigen presentation → makes infected cells better targets for cytotoxic T lymphocytes (CTLs)
• Activates NK cells to kill virally infected cells
• Triggers systemic flu-like symptoms (malaise, myalgia, chills, fever) — especially during viremia

Clinical Uses (Therapeutic)

IFN-α was one of the first cytokines introduced into clinical oncology and remains relevant in adjuvant regimens and pegylated long-acting forms. — Sabiston Textbook of Surgery

Mechanism of Action Diagram (IFN-α / IFN-β)

Interferon Beta (IFN-β) — Type I

Functions

• Produced mainly by fibroblasts (and other cells) in response to viral infection and dsRNA
• Shares the same IFNAR1/IFNAR2 receptor as IFN-α and the same antiviral signaling pathway (JAK-STAT)
• Upregulates MHC class I; activates NK cells; induces antiviral state
• In the CNS context: reduces neuroinflammation by:
  • Reducing T-cell migration across the blood-brain barrier
  • Shifting cytokine balance from pro-inflammatory (TH1) to anti-inflammatory (TH2)
  • Reducing MMP (matrix metalloproteinase) activity
  • Reducing MHC class II expression on CNS-resident cells

Clinical Uses (Therapeutic)

Interferon Gamma (IFN-γ) — Type II

Functions

• Structurally distinct from type I IFNs (<10% homology); uses a different receptor (IFNGR1/IFNGR2) but also signals via JAK-STAT (JAK1/JAK2 → STAT1)
• Produced by activated T cells (TH1) and NK cells/ILC1 — appears later in infection as part of the adaptive response
• The defining cytokine of the TH1 response and also known as macrophage-activating factor (MAF):
  • Activates macrophages → promotes production of reactive oxygen and nitrogen species → enhances intracellular killing (critical against mycobacteria, fungi, intracellular parasites)
  • Promotes phagocytosis, recruitment, and inflammatory responses
  • Upregulates MHC class II on macrophages → enhances antigen presentation to CD4 T cells
  • Directs monocyte differentiation toward a macrophage phenotype
• Inhibits viral replication (though weaker antiviral effect than type I IFNs)
• Blocks cell proliferation
• Activates macrophages to produce more IFN-α and IFN-β (amplification loop)

Clinical Uses (Therapeutic)

Common Side Effects of All Interferons

• Flu-like syndrome: fever, chills, myalgia, fatigue, headache (most common — caused by the systemic effects of the interferon response)
• Bone marrow suppression (neutropenia, thrombocytopenia)
• Elevated liver enzymes
• Depression and neuropsychiatric effects (especially IFN-α)
• Autoimmune phenomena (thyroiditis, SLE exacerbation — type I IFNs are a factor in SLE pathogenesis)
• Injection-site reactions

Summary Table

Anakinra — Mechanism of Action

What Is Anakinra?

Understanding IL-1 First (The Target)

• IL-1α and IL-1β are potent pro-inflammatory cytokines belonging to the IL-1 family
• They are primarily involved in innate immunity and drive systemic inflammation
• IL-1β is the dominant secreted form; it is produced as an inactive precursor (pro-IL-1β) that is cleaved by caspase-1 (activated by the NLRP3 inflammasome) into its active 17 kDa form
• When IL-1α or IL-1β binds the IL-1 receptor type I (IL-1RI) on cell surfaces, it recruits the IL-1 receptor accessory protein (IL-1RAcP), forming a signaling complex that activates NF-κB and MAPK pathways → triggering transcription of inflammatory genes (TNF, IL-6, IL-8, COX-2, adhesion molecules, MMPs)
• This cascade leads to: fever, synovitis, cartilage degradation, bone erosion, CRP production (via IL-6 → liver), and leukocyte recruitment
• IL-1β also stimulates further IL-6 production → hepatic acute-phase response (CRP ↑)

Mechanism of Action of Anakinra

Step-by-step:

1. Binding: Anakinra binds with high affinity to IL-1 receptor type I (IL-1RI) — with the same affinity as IL-1β itself
2. Competitive blockade: By occupying IL-1RI, it prevents both IL-1α and IL-1β from binding to their receptor
3. No signaling: Unlike IL-1α/β, anakinra binding does not recruit IL-1RAcP and does not trigger intracellular signaling — it is a pure antagonist (no agonist activity)
4. Downstream effects blocked:
   • No NF-κB or MAPK activation
   • No transcription of pro-inflammatory cytokines (IL-6, TNF, IL-8)
   • No COX-2 induction → reduced prostaglandin synthesis
   • No metalloproteinase (MMP) upregulation → reduced cartilage/bone destruction
   • Reduced CRP and acute-phase reactants (via IL-6 suppression)
   • Reduced neutrophil recruitment and activation

"Anakinra is a recombinant form of human interleukin 1 (IL-1) receptor antagonist (IL-1Ra). It blocks the effect of IL-1α and IL-1β on IL-1 receptors, hence decreasing the immune response in inflammatory diseases." — Katzung's Basic and Clinical Pharmacology, 16th Ed.

Contextual Pathway Diagram

Pharmacokinetics

Approved and Off-Label Uses

FDA-Approved

Key Off-Label Uses

• Adult-onset Still's disease (AOSD)
• Systemic juvenile idiopathic arthritis (sJIA)
• Recurrent pericarditis
• Gout (acute flares refractory to colchicine/NSAIDs)
• Hidradenitis suppurativa
• Pustular psoriasis
• Schnitzler syndrome
• COVID-19 (hyperinflammation/cytokine storm in non-intubated hospitalized patients — multiple trials showed mortality reduction)
• Kawasaki disease (refractory cases)
• STEMI — cardiac remodeling prevention (VCUART trials)

Comparison with Other IL-1 Inhibitors

Adverse Effects

• Injection-site reactions — most common (erythema, pain, swelling)
• Infections — increased risk (especially with concurrent TNF blockers — this combination is contraindicated)
• Neutropenia (monitor ANC)
• Headache
• Flu-like symptoms

Abatacept (Orencia)

What Is Abatacept?

1. The extracellular domain of human CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4, also called CD152)
2. The Fc region of human IgG1 (hinge, CH2, and CH3 domains — genetically modified to reduce complement activation)

Understanding the Target: T-Cell Costimulation

Mechanism of Action

1. The CTLA-4 domain of abatacept binds CD80 (B7-1) and CD86 (B7-2) on APCs with high affinity — higher than CD28
2. This competitively blocks CD28 from binding its co-stimulatory ligands on the APC
3. Signal 2 is denied → T cells cannot become fully activated
4. Without Signal 2, autoreactive T cells either:
   • Enter clonal anergy (functional unresponsiveness)
   • Fail to produce IL-2 → no proliferation or survival
   • Are more susceptible to apoptosis
5. Downstream consequences:
   • Reduced T-cell proliferation and differentiation
   • Reduced T-helper cell cytokine production (IL-17, IFN-γ, TNF)
   • Reduced B-cell activation (T-dependent antibody responses impaired → less RF and anti-CCP production)
   • Reduced synovial inflammation, osteoclast activation, and joint destruction
   • An additional cell-extrinsic mechanism: CTLA-4 binding can physically remove CD80/CD86 from the APC surface (transendocytosis), further limiting availability of costimulatory ligands

"Abatacept is designed to inhibit T-cell activation by binding to ligands CD80 and CD86 on APCs, ultimately blocking CD80 and CD86 interaction with CD28 on T cells." — Katzung's Basic and Clinical Pharmacology, 16th Ed.

"CTLA-4-Ig competitively inhibits CD28 binding to CD80 and CD86 and thus inhibits the activation of T cells." — Goodman & Gilman's, 13th Ed.

Pharmacokinetics

FDA-Approved Indications

Key Off-Label Uses

• Systemic lupus erythematosus (SLE)
• Primary Sjögren syndrome
• Type 1 diabetes mellitus (prevention — trials ongoing)
• Inflammatory bowel disease
• Takayasu arteritis
• Psoriasis vulgaris
• Dermatomyositis

Clinical Highlights

• In early rapidly progressive RA, methotrexate + abatacept was superior to methotrexate alone — achieving minimal disease activity as early as 2 months and significantly inhibiting radiographic progression at 1 year
• May prevent progression from undifferentiated inflammatory arthritis to established RA
• Associated with decreased cardiovascular risk and increased HDL compared to TNF inhibitors in RA patients
• Lower rate of latent TB reactivation compared to TNF inhibitors — useful when TB risk is elevated
• Not combined with TNF inhibitors or other biologics — unacceptable increase in serious infections

Adverse Effects

Abatacept vs. CTLA-4 Checkpoint Inhibitors